Guardant Health announced that Guardant360 CDx has received CE-marking under Europe’s in Vitro Diagnostic Medical Devices Regulation as a companion diagnostic (CDx) to identify patients with estrogen receptor… read more.
Johnson & Johnson announced new two-year results from the Phase 3 ICONIC-LEAD study evaluating ICOTYDE (icotrokinra), the first and only targeted oral peptide that precisely blocks the IL-23… read more.
Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced new envudeucitinib data from the ONWARD Phase 3 clinical… read more.
Mirum Pharmaceuticals, Inc. announced topline results from the Phase 3 EXPAND study evaluating LIVMARLI (maralixibat) for the treatment of cholestatic pruritus in patients aged 6 months or older… read more.
Johnson & Johnson announced that TREMFYA (guselkumab) met the primary and major secondary endpoints demonstrating both improvement in axial symptoms and reduction in inflammation by MRI assessment in… read more.
Eli Lilly and Company announced results from post-hoc analyses of ATTAIN-1 showing that Foundayo was associated with significant reductions in predicted 10-year risk of type 2 diabetes and… read more.
Bristol Myers Squibb announced positive topline results from the Phase 3 EXCALIBER-RRMM study, evaluating ZENBEXUS (iberdomide) in combination with daratumumab and dexamethasone (ZDd) in 800 patients with multiple… read more.
Tiziana Life Sciences, Ltd. announced that it has submitted a request to the FDA for Orphan Drug Designation for intranasal foralumab for the treatment of Multiple System Atrophy… read more.
Telix Pharmaceuticals Limited announces that the first patients in the United States (U.S.) have been dosed with Pixclara (floretyrosine F 18 or 18F-FET), its FDA-approved, amino acid positron… read more.
Novo Nordisk announced new retrospective real-world evidence in adults with type 2 diabetes treated with once-weekly semaglutide injection 1 mg. In the analysis, adults who escalated to semaglutide… read more.
Moberg Pharma AB announced the publication of new analyses demonstrating potent antifungal activity of terbinafine against dermatophytes causing onychomycosis. Importantly, mycological cure with Mob-015 was achieved across the… read more.
NICE(UK): Trastuzumab deruxtecan can be used, within its marketing authorisation, as an option to treat HER2-low metastatic or unresectable breast cancer in adults after: i) chemotherapy in the… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
